POEMS syndrome with multiple ganglioside/paraneoplastic antibodies misdiagnosed as CIDP: a case report - Scorecard - MDSpire

POEMS syndrome with multiple ganglioside/paraneoplastic antibodies misdiagnosed as CIDP: a case report

  • By

  • Mengmeng Fan

  • Jiaxiu He

  • Shihui Sun

  • Linyuan He

  • Zhao Zhong

  • April 30, 2026

  • 0 min

Share

Clinical Scorecard: Misdiagnosis of POEMS Syndrome as CIDP: A Case Study Involving Multiple Ganglioside and Paraneoplastic Antibodies

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationAdults with polyneuropathy and systemic symptoms, particularly those aged 40-70.
Care Setting

Key Highlights

  • Emphasize the clinical implications of misdiagnosis and the need for accurate differentiation.

Guideline-Based Recommendations

Diagnosis

  • Utilize specialized laboratory tests such as serum protein electrophoresis and imaging studies like MRI or CT scans.

Management

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Consider treatments such as corticosteroids or immunotherapy for underlying plasma cell dyscrasias.

        Clinical Best Practices

        • Include nerve conduction studies and skin biopsies as part of comprehensive diagnostic evaluations.

        References

        Original Source(s)

        POEMS syndrome with multiple ganglioside/paraneoplastic antibodies misdiagnosed as CIDP: a case report

        • by Mengmeng Fan, Jiaxiu He, Shihui Sun, Linyuan He, Zhao Zhong

        • April 30, 2026

        Related Content

        Familial associations of lymphoma and myeloma with autoimmune diseases

        Research Leaders Across New York State Form Empire State Cellular Therapy Consortium

        To expand on early progress in the emerging field of cell and gene therapy, five research centers across New York State are collaborating to develop new cell therapies for cancer and other diseases.

        • by

        • July 29, 2025

        • 7 min
        Advances in Hodgkin Lymphoma Treatment: Clinical Considerations for Managing Toxicities in Nivolumab-AVD Therapy

        One of the most promising developments in advanced-stage Hodgkin lymphoma is the nivolumab-AVD regimen, which combines nivolumab with doxorubicin, vinblastine, and dacarbazine. This article provides practical knowledge for advanced practitioners to effectively manage the most common toxicities associated with nivolumab-AVD.